Journal Mobile Options
Table of Contents
Vol. 24, No. 3, 2006
Issue release date: April 2006
Blood Purif 2006;24:319–326
(DOI:10.1159/000091851)

Physiological Response to Superantigen-Adsorbing Hemoperfusion in Toxin-Concentration-Controlled Septic Swine

Miwa K. · Fukuyama M. · Matsuno N. · Shimada K. · Ikeda K. · Ikeda T.
aNew Frontiers Research Laboratories, Toray Industries, Inc., Kanagawa; bSpecialty Material Research Laboratories, Toray Industries Inc., Shiga; cFifth Department of Surgery, Hachioji Medical Center, Tokyo Medical University, and dDivision of Critical Care and Emergency Medicine, Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: Superantigens are suspected of being potent initiators of gram-positive sepsis, and new therapies for superantigen elimination are required. The effects of hemoadsorption with a superantigen-adsorbing device (SAAD) were evaluated in septic swine. Methods: Toxic shock syndrome toxin-1 (TSST-1) was infused, and blood concentration was maintained at the clinical level for 6 h. Endotoxin was then infused to induce lethal shock. All animals were hemoperfused with SAAD or a control column for 8 h and changes in pathological parameters and mortality were examined. Results: Animals perfused with SAAD had a highly significant (p < 0.01) survival advantage compared with control groups at 24 h after initiation of the TSST-1 infusion. SAAD also suppressed the increase in the arteriovenous shunt ratio and decrease of partial arterial oxygen pressure at 6 h after TSST-1 infusion initiation. Conclusion: We suggest that there is a potential application of SAAD in treating superantigen-induced respiratory dysfunction and sepsis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Sriskandan S, Cohen J: Gram-positive sepsis: mechanisms and differences from gram-negative sepsis. Infect Dis Clin N Am 1999;13:397–412.
  2. Opal SM, Cohen J: Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? Crit Care Med 1999;27:1608–1616.
  3. Cohen J: Mechanisms of tissue injury in sepsis: contrasts between gram positive and gram negative infection. J Chemother 2001;1:153–158.

    External Resources

  4. Llewelyn M, Cohen J: Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002;2:156–162.
  5. Proft T, Fraser JD: Bacterial superantigens. Clin Exp Immunol 2003;133:299–306.
  6. Miwa K, Fukuyama M, Kunitomo T, Igarashi H: Rapid assay for detection of toxic shock syndrome toxin 1 from human sera. J Clin Microbiol 1994;32:539–542.
  7. Sriskandan S, Moyes D, Cohen J: Detection of circulating bacterial superantigen and lymphotoxin-alpha in patients with streptococcal toxic-shock syndrome. Lancet 1996;348:1315–1316.
  8. de Azavedo JC: Animal models for toxic shock syndrome: overview. Rev Infect Dis 1989;11:S205–S209.
  9. Azuma K, Koike K, Kobayashi T, Mochizuki T, Mashiko K, Yamamoto Y: Detection of circulating superantigens in an intensive care unit population. Int J Infect Dis 2004;8:292–298.
  10. Miwa K, Fukuyama M, Ida N, Igarashi H, Uchiyama T: Preparation of superantigen-adsorbing device and its superantigen removal efficacies in vitro and in vivo. Int J Infect Dis 2003;7:21–28.
  11. Nagaki M, Hughes RD, Keane HM, Goka J, Williams R: Clearance and tissue distribution of staphylococcal enterotoxin A in the rat potential use of adsorbents for removal from plasma. J Med Microbiol 1993;38:354–359.
  12. Fenwick P, Ryan C, Sriskandan S, Cohen J: Application of a rat model of streptococcal shock to evaluate on-line hemoperfusion and removal of circulating superantigens. Crit Care Med 2003;31:171–178.
  13. Fukuyama M, Miwa K, Shibayama N, Ogura S, Nishiyama T, Maekawa N: Mixed bacterial infection model of sepsis in rabbits and efficacy evaluation of superantigen-adsorption device. Blood Purif 2005;23:119–127.
  14. Miwa K, Fukuyama M, Matsuno N, Masuda S, Ikeda K, Ikeda T: Superantigen induced multiple organ dysfunction in a toxin-concentration controlled and sequential parameter monitored swine sepsis model. Int J Infect Dis, in press.
  15. Igarashi H, Fujikawa H, Usami H, Kawabata S, Morita T: Purification and characterization of Staphylococcus aureus FRI 1169 and 587 toxic shock syndrome exotoxins. Infect Immun 1984;44:175–181.
  16. Bernard GR, Artigas A, Brigham KL, et al: Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. Intens Care Med 1994;20:225–232.
  17. Holtfreter S, Bröker BM: Staphylococcal superantigens: do they play a role in sepsis? 2005;53:13–27.
  18. Igarashi H, Fujikawa H, Usami H: Effect of drug on the pyrogenicity of toxic shock syndrome toxin-1 and its capacity to enhance susceptibility to the lethal effect of endotoxin shock in rabbis. Rev Infect Dis 1989;2:S210–S213.
  19. Blank C, Luz A, Bendigs S, Erdmann A, Wagner H, Heeg K: Superantigen and endotoxin synergize in the induction of lethal shock. Eur J Immunol 1997;27:825–833.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50